SCHEMBL7123423

SCHEMBL7123423

COc1cc(Sc2ccc(C(=O)N[C@@H]3C[C@H]4CC[C@@H]3N4)cc2)ns1

nearest known ligand 0.36

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 4/20 0.36
SLC6A3 Q01959 4/20 0.36
SLC6A2 P23975 3/20 0.36
KDM1A O60341 1/20 0.34
CHRNA7 P36544 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
HTR3E A5X5Y0 1/20 0.33
HTR3B O95264 1/20 0.33
HTR3A P46098 1/20 0.33
HTR3D Q70Z44 1/20 0.33
HTR3C Q8WXA8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7124968 0.87 CHRNA7 (0.35) SLC6A4SLC6A3SLC6A2KDM1ACHRNA7
SCHEMBL7120644 0.86 CHRNA7 (0.34) SLC6A4SLC6A3SLC6A2KDM1ACHRNA7
SCHEMBL7124195 0.85 CHRNA7 (0.35) SLC6A4SLC6A3SLC6A2CHRNA7MEN1
SCHEMBL7119284 0.84 CHRNA7 (0.33) SLC6A4SLC6A3SLC6A2CHRNA7
SCHEMBL7124876 0.83 EPHX2 (0.35) SLC6A4SLC6A3SLC6A2KDM1ACHRNA7
SCHEMBL7116361 0.83 CHRNA7 (0.33) SLC6A4SLC6A3SLC6A2KDM1ACHRNA7
SCHEMBL7119278 0.82 GRM5 (0.36) KDM1AHTR3EHTR3BHTR3AHTR3D
SCHEMBL7120663 0.82 SLC6A2 (0.38) SLC6A4SLC6A3SLC6A2CHRNA7HTR3E
SCHEMBL7115178 0.81 SLC6A4 (0.38) SLC6A4SLC6A3SLC6A2KDM1AHTR3E
SCHEMBL7122356 0.81 HDAC6 (0.37) SLC6A4SLC6A3SLC6A2CHRNA7HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 SLC6A4 2137/4885SLC6A3 2265/4885SLC6A2 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.